Congress Materials – Journal of the Advanced Practitioner in Oncology (JADPRO 2024)
2024 Journal of the Advanced Practitioner in Oncology | Nov 14-17 | Grapevine, TX
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutated, Advanced Non-small Cell Lung Cancer After Disease Progression on Osimertinib: 2nd Interim Overall Survival From MARIPOSA-2
Sanjay Popat, Karen L. Reckamp, Raffaele Califano, Se-Hoon Lee, Barbara Melosky, Jie Wang, Yongsheng Wang, Maria del Rosario Garcia Campelo, Enriqueta Felip, Nicolas Girard, Ryan D. Gentzler, William Nassib William Jr, Toshiaki Takahashi, Misako Nagasaka, Joshua M. Bauml, Sujay Shah, Brooke Diorio, Pei-Ling Chu, Byoung Chul Cho, Antonio Passaro
Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
Shirish M. Gadgeel, Byoung Chul Cho, Shun Lu, Enriqueta Felip, Hidetoshi Hayashi, Alexander I. Spira, Benjamin Besse, Michael Thomas, Scott Owen, Yu Jung Kim, Se-Hoon Lee, Josiane Mourão Dias, Yun-Gyoo Lee, Yanqiu Zhao, Yong Fang, Nicolas Girard, Zhe Liu, Ping Sun, Sulene Cunha Sousa Oliveira, Hong Shen, Luis Paz-Ares, Shingo Matsumoto, Hiroshi Tanaka, Azura Rozila Ahmad, Timur Andabekov, Patrapim Sunpaweravong, Ozgur Ozyilkan, James Chih-Hsin Yang, Maya Gottfried, Osvaldo Hernandez, Martin Kimmich, Diego Cortinovis, Diego Lucas Kaen, Lizbett Vanessa García Montes, Sanjay Popat, Thomas Newsom-Davis, David Robert Spigel, John Xie, Tao Sun, Elizabeth Fennema, Mahesh Daksh, Mariah Ennis, Seema Sethi, Joshua M. Bauml, Danny Nguyen
Effect of Amivantamab Dose Interruptions on Efficacy and Safety of First-line Amivantamab Plus Lazertinib in EGFR-mutant Advanced NSCLC: Exploratory Analyses from the MARIPOSA study
Maria del Rosario Garcia Campelo, Byoung Chul Cho, Nicolas Girard, Shun Lu, Hiroshige Yoshioka, Jong-Seok Lee, Se-Hoon Lee, Baogang Liu, Mehmet Ali Sendur, Benjamin Besse, Alexander I. Spira, Enriqueta Felip, Andres Aguilar, Joshua K Sabari, Sanjay Popat, Parthiv Mahadevia, Seema Sethi, Joshua M. Bauml, Yuriy Ostapenko
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with advanced EGFR-mutated, non-small cell lung cancer (NSCLC): Interim results from the phase 2 PALOMA-2 study
Sun Min Lim, Jiunn Liang Tan, Josiane Mourão Dias, Pei Jye Voon, Soon Hin How, Xiangdong Zhou, Hailin Xiong, Bartomeu Massutí, Louise Medley, Misako Nagasaka, David Vicente, Nicolas Girard, Achim Rittmeyer, Dana-Adriana Botesteanu, Ali Alhadab, Janine Mahoney, Jie Zhang, Joshua M. Bauml, Mahadi Baig, Susan C. Scott
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.